Group One Trading
JUNO

Group One Trading’s Juno Therapeutics, Inc. JUNO Stock Holding History

Group One Trading’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-219,000
Closed -$10M – 5685
2017
Q4 		$10M Sell
219,000
-124,300
-36% -$6.2M 0.07% 338
2017
Q3 		$15.4M Buy
343,300
+157,800
+85% +$5.38M 0.14% 148
2017
Q2 		$5.54M Buy
185,500
+66,100
+55% +$1.63M 0.06% 408
2017
Q1 		$2.65M Sell
119,400
-113,400
-49% -$2.43M 0.03% 690
2016
Q4 		$4.39M Buy
232,800
+75,500
+48% +$1.85M 0.04% 488
2016
Q3 		$4.72M Buy
157,300
+78,000
+98% +$2.43M 0.05% 433
2016
Q2 		$3.05M Buy
79,300
+3,700
+5% +$154K 0.04% 597
2016
Q1 		$2.88M Sell
75,600
-43,300
-36% -$1.51M 0.04% 584
2015
Q4 		$5.23M Buy
118,900
+71,700
+152% +$3.56M 0.06% 350
2015
Q3 		$1.92M Sell
47,200
-93,000
-66% -$4.08M 0.03% 809
2015
Q2 		$7.48M Buy
140,200
+98,900
+239% +$5.25M 0.1% 205
2015
Q1 		$2.5M Buy
+41,300
New +$2M 0.04% 531

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Group One Trading's JUNO Position: Q3 2017 in Review

Group One Trading sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 79,579 shares — an estimated $2.71M sold.

Group One Trading first reported a position in JUNO in Q1 2015 and held it in 9 quarters. The position peaked at $2.91M in Q4 2016. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

  • Group One Trading reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Group One Trading sold 79,579 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $2.71M.
  • Group One Trading first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 9 quarters.
  • Group One Trading's Juno Therapeutics, Inc. position peaked at $2.91M in Q4 2016.
  • 210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Group One Trading's 13F filing for Q3 2017, filed 15 Nov 2017.